Elizabeth B Burgener

Elizabeth B Burgener, MD is a pediatric pulmonologist and physician scientist. After receiving her B.A. at Stanford University, she completed medical school at the University of Texas Health Science Center at San Antonio in 2011. She then returned to Stanford for residency in Pediatrics followed by a year as a Pediatric Chief Resident prior to fellowship in pediatric pulmonary medicine during which she also completed post-doctoral training in microbiology and immunology in the Bollyky Lab. She spent another 5 years at Stanford developing her research program before she moved to Children’s Hospital of Los Angeles and Keck School of Medicine at USC in summer of 2023. She is currently an Assistant Professor in the division of Pediatric Pulmonology & Sleep Medicine in the department of Pediatrics where she treats patients with pulmonary disease as well as conducting translational research focused on infection and bacteriophage in the cystic fibrosis airways.

• UTHSCSA: Alpha Omega Alpha, 2011
• Maternal Child Health Institute, Stanford University: Clinical Trainee Award, 2015
   – 2018
• Translational Research and Applied Medicine, Stanford University: Pilot Grant, 2016
   – 2018
• Stanford University: T32 Program In Pulmonary Biology, 2016
   – 2018
• Respiratory Disease Young Investigators Forum, National Jewish Health, Washington, DC: First Place in Clinical Research, 2018
• Department of Pediatrics, Stanford University: Bridge to K Award, 2018
   – 2021
• Francis Family Foundation: Parker B Francis Fellowship, 2018
   – 2021
• Vertex Pharmaceuticals, Inc.: Cystic Fibrosis Research Innovation Award, 2019
• Cystic Fibrosis Foundation: Harry Shwachman Clinical Investigator Award, 2020
   – 2023

• Stanford University, Stanford, CA — BA — 6/2005 — Human Biology
• University of Texas Health Science Center at San Antonio, San Antonio, TX — MD — 05/2011 — Medicine
• Stanford Hospital & Clinics, Stanford, CA — 06/2014 — Pediatrics
• Stanford Hospital & Clinics, Stanford, CA — 6/2018 — Pediatric Pulmonology

• cystic fibrosis
• Pseudomonas aeruginosa
• bacteriophage
• pulmonary disease

• Bacterial Receptors but Not Anti-Phage Defense Mechanisms Determine Host Range for a Pair of Pseudomonas aeruginosa Lytic Phages. bioRxiv. 2026 Feb 11.. View in PubMed
• Phage-Mediated Iron Acquisition by Pseudomonas aeruginosa. bioRxiv. 2026 Jan 26.. View in PubMed
• Evolutionary loss of an antibiotic efflux pump increases Pseudomonas aeruginosa quorum sensing mediated virulence in vivo. Nat Commun. 2025 Sep 25; 16(1):8397.. View in PubMed
• New Pseudomonas infections drive Pf phage transmission in CF airways. JCI Insight. 2025 06 09; 10(11).. View in PubMed
• Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis. Pediatr Pulmonol. 2025 Mar; 60(3):e71019.. View in PubMed
• Prophages are infrequently associated with antibiotic resistance in Pseudomonas aeruginosa clinical isolates. mSphere. 2025 Mar 25; 10(3):e0090424.. View in PubMed
• Prophages are Infrequently Associated With Antibiotic Resistance in Pseudomonas aeruginosa Clinical Isolates. bioRxiv. 2025 Jan 18.. View in PubMed
• Pseudomonas superinfection drives Pf phage transmission within airway infections in patients with cystic fibrosis. bioRxiv. 2025 Jan 14.. View in PubMed
• A blueprint for broadly effective bacteriophage-antibiotic cocktails against bacterial infections. Nat Commun. 2024 11 28; 15(1):9987.. View in PubMed
• Evolutionary loss of an antibiotic efflux pump increases Pseudomonas aeruginosa quorum sensing mediated virulence in vivo. Res Sq. 2024 Nov 12.. View in PubMed
• Pf bacteriophage is associated with decline in lung function in a longitudinal cohort of patients with cystic fibrosis and Pseudomonas airway infection. J Cyst Fibros. 2025 Mar; 24(2):345-352.. View in PubMed
• The lysogenic filamentous Pseudomonas bacteriophage phage Pf slows mucociliary transport. PNAS Nexus. 2024 Sep; 3(9):pgae390.. View in PubMed
• Pf bacteriophages hinder sputum antibiotic diffusion via electrostatic binding. Sci Adv. 2024 05 31; 10(22):eadl5576.. View in PubMed
• Targeted deletion of Pf prophages from diverse Pseudomonas aeruginosa isolates has differential impacts on quorum sensing and virulence traits. J Bacteriol. 2024 05 23; 206(5):e0040223.. View in PubMed
• Pf bacteriophages hinder sputum antibiotic diffusion via electrostatic binding. bioRxiv. 2024 Mar 10.. View in PubMed
• Highly effective cystic fibrosis transmembrane conductance (regulator) modulator therapy: shifting the curve for most while leaving some further behind. Curr Opin Pediatr. 2024 06 01; 36(3):290-295.. View in PubMed
• The Inovirus Pf4 Triggers Antiviral Responses and Disrupts the Proliferation of Airway Basal Epithelial Cells. Viruses. 2024 01 22; 16(1).. View in PubMed
• Targeted deletion of Pf prophages from diverse Pseudomonas aeruginosa isolates impacts quorum sensing and virulence traits. bioRxiv. 2023 Nov 19.. View in PubMed
• Delivering a New Future for People With Cystic Fibrosis. Pediatrics. 2023 10 01; 152(4).. View in PubMed
• Bacteriophage and Bacterial Susceptibility, Resistance, and Tolerance to Antibiotics. Pharmaceutics. 2022 Jul 07; 14(7).. View in PubMed
• Biochemical, biophysical, and immunological characterization of respiratory secretions in severe SARS-CoV-2 infections. JCI Insight. 2022 06 22; 7(12).. View in PubMed
• Filamentous bacteriophage delays healing of Pseudomonas-infected wounds. Cell Rep Med. 2022 06 21; 3(6):100656.. View in PubMed
• Oral hymecromone decreases hyaluronan in human study participants. J Clin Invest. 2022 05 02; 132(9).. View in PubMed
• Biochemical, Biophysical, and Immunological Characterization of Respiratory Secretions in Severe SARS-CoV-2 (COVID-19) Infections. medRxiv. 2022 Apr 04.. View in PubMed
• Biochemical and Biophysical Characterization of Respiratory Secretions in Severe SARS-CoV-2 (COVID-19) Infections. medRxiv. 2021 Aug 19.. View in PubMed
• The Safety and Toxicity of Phage Therapy: A Review of Animal and Clinical Studies. Viruses. 2021 06 29; 13(7).. View in PubMed
• Filamentous Bacteriophages and the Competitive Interaction between Pseudomonas aeruginosa Strains under Antibiotic Treatment: a Modeling Study. mSystems. 2021 Jun 29; 6(3):e0019321.. View in PubMed
• Dynamic light scattering microrheology for soft and living materials. Soft Matter. 2021 Feb 21; 17(7):1929-1939.. View in PubMed
• Area under the curve achievement of once daily tobramycin in children with cystic fibrosis during clinical care. Pediatr Pulmonol. 2020 12; 55(12):3343-3350.. View in PubMed
• Methods for Extraction and Detection of Pf Bacteriophage DNA from the Sputum of Patients with Cystic Fibrosis. Phage (New Rochelle). 2020 06 01; 1(2):100-108.. View in PubMed
• Pf Bacteriophage and Their Impact on Pseudomonas Virulence, Mammalian Immunity, and Chronic Infections. Front Immunol. 2020; 11:244.. View in PubMed
• Filamentous bacteriophages are associated with chronic Pseudomonas lung infections and antibiotic resistance in cystic fibrosis. Sci Transl Med. 2019 04 17; 11(488).. View in PubMed
• Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis. Curr Opin Pediatr. 2018 06; 30(3):372-377.. View in PubMed
• Teaching High-Value Care in Pediatrics: A National Survey of Current Practices and Guide for Future Curriculum Development. J Grad Med Educ. 2017 Dec; 9(6):741-747.. View in PubMed
• Clinical characteristics and outcomes of pediatric patients with CMV DNA detection in bronchoalveolar lavage fluid. Pediatr Pulmonol. 2017 01; 52(1):112-118.. View in PubMed
• Molecular and Culture-Based Bronchoalveolar Lavage Fluid Testing for the Diagnosis of Cytomegalovirus Pneumonitis. Open Forum Infect Dis. 2016 Jan; 3(1):ofv212.. View in PubMed
• Index of suspicion. Pediatr Rev. 2014 Oct; 35(10):439-46.. View in PubMed

• Beringer, Paul
• Smith, Beth
• Paranos, Paschalis
• Neely, Michael
• Maher, Toby
• Rao, Adupa